Vanessa Doria

Vanessa Doria

orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 March 2020 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
RMRosalinda Madonna
Rosalinda Madonna
Damiana PieragostinoDamiana Pieragostino
Damiana Pieragostino
Maria Concetta CufaroMaria Concetta Cufaro
Maria Concetta Cufaro
VDVanessa Doria
Vanessa Doria
PIERO DEL BOCCIOPIERO DEL BOCCIO
PIERO DEL BOCCIO
GMGiuseppe Mercuro
Giuseppe Mercuro
Ponatinib, a third-generation tyrosine kinase inhibitor (TKI), is the only approved TKI that is effective against T315I mutations in patients with chronic myeloid leukemia (CML). Specific activation of Notch signaling in CML cells by ponatinib can be considered as the “on-target effect” on the tumor and represents a therapeutic approach for CML. Nevertheless, ponatinib-induced vascular toxicity remains a serious concern, with underlying mechanisms being poorly understood. We aimed to determine the mechanisms of ponatinib-induced vascular toxicity, defining associated signaling pathways and identifying potential rescue strategies. We exposed human umbilical endothelial cells (HUVECs) to ponatinib or vehicle in the presence or absence of the neutralizing factor anti-Notch-1 antibody for exposure times of 0–72 h. Label-free proteomics and network analysis showed that protein cargo of HUVECs treated with ponatinib triggered apoptosis and inhibited vasculature development. We validated the proteomic data showing the inhibition of matrigel tube formation, an up-regulation of cleaved caspase-3 and a downregulation of phosphorylated AKT and phosphorylated eNOS. We delineated the signaling of ponatinib-induced vascular toxicity, demonstrating that ponatinib inhibits endothelial survival, reduces angiogenesis and induces endothelial senescence and apoptosis via the Notch-1 pathway. Ponatinib induced endothelial toxicity in vitro. Hyperactivation of Notch-1 in the vessels can lead to abnormal vascular development and vascular dysfunction. By hyperactivating Notch-1 in the vessels, ponatinib exerts an “on-target off tumor effect”, which leads to deleterious effects and may explain the drug’s vasculotoxicity. Selective blockade of Notch-1 prevented ponatinib-induced vascular toxicity.

1 June 2019 in Journal of Molecular and Cellular Cardiology
Verified
Journal Article
Closed access
RMRosalinda Madonna
Rosalinda Madonna
SAStefania Angelucci
Stefania Angelucci
FGFabrizio Di Giuseppe
Fabrizio Di Giuseppe
VDVanessa Doria
Vanessa Doria
ZGZoltán Giricz
Zoltán Giricz
Raffaele De CaterinaRaffaele De Caterina
Raffaele De Caterina

13 October 2022 in Vascular Pharmacology
Verified
Journal Article
Closed access
CLChiara Lenzi
Chiara Lenzi
RMRosalinda Madonna
Rosalinda Madonna
Damiana PieragostinoDamiana Pieragostino
Damiana Pieragostino
Maria Concetta CufaroMaria Concetta Cufaro
Maria Concetta Cufaro
PIERO DEL BOCCIOPIERO DEL BOCCIO
PIERO DEL BOCCIO
CCCaterina Caterina
Caterina Caterina